四川大学华西医院2011年老年门诊肺癌患者用药分析

Drug Use Analysis on Over-60-year Outpatients with Lung Cancer in the West China Hospital of Sichuan University in 2011

目的回顾性分析四川大学华西医院2011年门诊老年(≥60岁)肺癌患者用药结构及用药合理性。方法从四川大学华西医院信息系统提取相关信息,采用Excel 2010软件进行统计分析。结果 1该院2011年≥60岁门诊肺癌患者共17296人次,未用药者12606人次,占72.88%;用药人次中75.76%仅用1种药物。2共使用肿瘤相关药5类、56种,总用药频次6460人次,人均费用2219.38元。用药频次前3位依次为中成药(28.50%)、其他治疗药物(24.91%)和对因治疗药物(22.23%)。3对因治疗药物中,用药频次小分子靶向药物占59.96%,前3位药物依次为吉非替尼、重组人血管内皮抑制素和厄洛替尼。4对症治疗药物中,镇痛药物占43.65%,前3位药物依次为盐酸曲马多缓释片、唑来膦酸钠和氨酚羟考酮。5抗不良反应(ADR)治疗药物中,保肝药物占40.97%,前3位药物依次为盐酸帕洛诺司琼、甘草酸二铵和泮托拉唑。6其他治疗药物包括免疫增强剂和造血生长因子,分别占62.65%和37.35%;前3位药物依次为胸腺法新、胸腺五肽和重组白介素-11。7中成药中,回生口服液、复方斑鳌胶囊、百令胶囊用药频次分别占51.06%、15.37%和13.91%。8用药频次居前10位的药物依次为回生口服液、吉非替尼和胸腺法新、胸腺五肽、重组白介素-11、复方斑螯胶囊、重组人血管内皮抑制素、盐酸曲马多缓释片、唑来膦酸钠和百令胶囊。结论四川大学华西医院2011年老年门诊肺癌患者抗肿瘤治疗以小分子靶向单药为主,辅助治疗中镇痛、止咳和预防骨相关事件治疗比例较大,此外,中成药常用。

Objective To retrospectively investigate the medication structure and evaluate the rationality among over-60-year outpatients with lung cancer in the West China Hospital of Sichuan University in 201 i. Methods The data was extracted from the hospital information system （HIS）. Excel 2010 software was used for statistical analysis. Re- sults a） The total of over-60-year outpatients with lung cancer were 17 296 person-times, of which 12 606 persons-times patients with no medication accounted for 72.88%. The monotherapy in patients with medication accounted for 75.76%. b） There were 5 types of tumour related drugs, including 56 kinds of different drugs, and the total frequency was 6 460 and the average cost was 2 219.38 yuan. The first three drugs classified by 5 types were traditional Chinese drugs （TCM, 28.50%）, other therapy （24.91%）, and etiological treatment （22.23%）. c） For etiological treatment, tyrosine kinase inhibi- tors （TKI） accounted for 59.96%, and the first three drugs were gefitinib, recombinant human endostatin, and erlotinib, d） For symptomatic treatment, analgesic drugs accounted for 43.65%; and the first three drugs were tramadol hydrochloride sustained-release tablets, sodium zoledronic oxycodone, and acetaminophen, e） For ADR therapy, liver drugs accounted for 40.97%; and the first three drugs were palonosetron hydrochloride, licorice, and diammonium pantoprazole, f） Other treatment involved immunopotentiating drugs and hematopoietic growth factors, the ratios were 62.65% and 37.35%, and the first three drugs were thymalfasin, thymopentin, and recombinant interleukin-11, g） Huisheng, Banao capsule and Bailing capsule were at the first three usage in TCM, the ratios of which were 51.06%, 15.37%, and 13.91%. h） The top ten drugs were Huisheng oral liquid, gefitinib and thymus AFP, thymopentin recombinant interleukin-11, chelating compound spot capsules, recombinant human endostatin, tramadol hydrochloride extended release tablets, sodium, zole-dronic, and Bailing capsule. Conclusion The antitumor therapies were mainly TKI single drug regimen for over-60-year outpatients with lung cancer in the West China hospital of Sichuan University in 2011. The most frequently used ad）uvant therapies are antalgic, antitussive and skeletal related events prevention drugs. Besides, Chinese patent medicines are in common use as well.